Cogent Biosciences, Inc. (COGT) › Cash & EquivalentsCogent Biosciences, Inc. (COGT) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2017: $28.27M2018: $55.67M2019: $37.42M2020: $242.19M2021: $219.68M2022: $139.89M2023: $53.23M2024: $98.17M2025: $312.01M$312.01M2017Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$312.01M+217.8%2024$98.17M+84.4%2023$53.23M-61.9%2022$139.89M-36.3%2021$219.68M-9.3%2020$242.19M+547.2%2019$37.42M-32.8%2018$55.67M+96.9%2017$28.27M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share